| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
This week, Pfizer Inc (NYSE:PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V. (NASDAQ:MYNZ) applied for Breakthrough Device Designation to the US Food and Drug Administration (FDA) for its revolutionary colorectal cancer (CRC) screening test, which subject to the review, would significantly accelerate the approval process.
Pfizer entered a multi-year partnership with Evotec to work together to advance scientific discovery for diseases with unmet need. Together with Evotec, Pfizer will focus on research for metabolic and infectious diseases. Everest chief business officer tated the company is honored to join Pfizer in focusing on diseases with severe unmet medical needsthat impact millions across the globe whose vital mechanism has been disrupted. Everest is excited to explore innovative therapies by supporting Pfizer with research and development activites at its facilities in France, a country praised for developing a strong biopharmaceutical ecosystem. Biopharmaceuticals are the new generation of complex medicines whose active substance is derived from a living source by using cutting-edge methods. In addition to its high quality research infrastructure, France ranks second in Europe for its development pipeline that consists of 584 products, according to France Biolead.
Mainz Biomed developed a non-invasive CRC test, ColoAlert. Prior to the FDA application, Mainz Biomed reported positive results from its clinical studies ColoFuture and eAArly Detect, as well as data from a pooled study including both the European and the US data, that showed sensitivity of 97% for CRC, as well as 88% for advanced adenomas which are precancerous lesions, with a specificity of 93%. ColoAlert is already being marketed across Europe, but the next-generation test includes novel mRNA biomarkers that will be used in the pivotal registration study titled ReconAAsense.
Along with its proprietary portfolio of mRNA biomarkers, Mainz Biomed complemented the Fecal Immunochemical Test (FIT) with an advanced AI and machine learning algorithm.
Besides providing an easy, non-invasive, at-home solution for CRC screening that is often avoided due to the inconvenience of colonoscopy, Mainz Biomed also went a step further by providing the opportunity to prevent CRC altogether by allowing the treatment of advanced adenoma before they advance to a cancerous state.
All in all, the above stories are examples of embracing emerging technology for good, which will undoubtedly also do good to their financials, if successful.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.
